procaine has been researched along with Myocardial Ischemia in 19 studies
Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).
procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The reduction in hypothermia and ischaemia-induced reperfusion arrhythmias by the addition of sevoflurane to HTK solution may be related to the phosphorylation of Cx43 at serine 368." | 7.91 | Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368. ( Gao, H; Gao, J; Li, WC; Wang, ZJ, 2019) |
| "Regional myocardial ischemia was induced by occlusion of a diagonal branch of left anterior descending coronary artery of anesthetized cats." | 5.35 | Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2? ( Fu, LW; Longhurst, JC; Phan, A, 2008) |
| "The reduction in hypothermia and ischaemia-induced reperfusion arrhythmias by the addition of sevoflurane to HTK solution may be related to the phosphorylation of Cx43 at serine 368." | 3.91 | Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368. ( Gao, H; Gao, J; Li, WC; Wang, ZJ, 2019) |
| " In our study we compared myocardial protection in isolated coronary bypass with a short period of ischemia using low dosage HTK and cold crystalloid cardioplegia." | 2.71 | Low-dose histidine-tryptophan-ketoglutarate solution for myocardial protection. ( Akay, T; Arslan, A; Aslamaci, S; Gultekin, B; Ozkan, S; Sezgin, A; Tasdelen, A; Uguz, E, 2005) |
| "Regional myocardial ischemia was induced by occlusion of a diagonal branch of left anterior descending coronary artery of anesthetized cats." | 1.35 | Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2? ( Fu, LW; Longhurst, JC; Phan, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, J | 1 |
| Liu, X | 1 |
| Wang, M | 1 |
| Wang, X | 1 |
| Su, S | 1 |
| Li, WC | 1 |
| Gao, H | 1 |
| Gao, J | 1 |
| Wang, ZJ | 1 |
| Fu, LW | 1 |
| Phan, A | 1 |
| Longhurst, JC | 1 |
| Jacob, M | 1 |
| Paul, O | 1 |
| Mehringer, L | 1 |
| Chappell, D | 1 |
| Rehm, M | 1 |
| Welsch, U | 1 |
| Kaczmarek, I | 1 |
| Conzen, P | 1 |
| Becker, BF | 1 |
| Ikizler, M | 1 |
| Dernek, S | 1 |
| Sevin, B | 1 |
| Maxey, TS | 1 |
| Kural, T | 1 |
| Yotsumoto, G | 1 |
| Jeschkeit-Schubbert, S | 1 |
| Funcke, C | 1 |
| Kuhn-Régnier, F | 1 |
| Fischer, JH | 1 |
| Harlan, BJ | 1 |
| Ross, D | 1 |
| Macmanus, Q | 1 |
| Knight, R | 1 |
| Luber, J | 1 |
| Starr, A | 1 |
| Keembiyage, RD | 1 |
| Newland, HS | 1 |
| Lai, C | 1 |
| Wei, J | 1 |
| Chang, CY | 1 |
| Chuang, YC | 1 |
| Su, SH | 1 |
| Lee, KC | 1 |
| Tung, DY | 1 |
| Lee, SL | 1 |
| Lee, WC | 1 |
| Arslan, A | 1 |
| Sezgin, A | 1 |
| Gultekin, B | 1 |
| Ozkan, S | 1 |
| Akay, T | 1 |
| Uguz, E | 1 |
| Tasdelen, A | 1 |
| Aslamaci, S | 1 |
| Kossitsky, GI | 1 |
| Kalmykov, VW | 1 |
| Bolotova, MF | 1 |
| Mühlfeld, C | 1 |
| Urru, M | 1 |
| Rümelin, R | 1 |
| Mirzaie, M | 1 |
| Schöndube, F | 1 |
| Richter, J | 5 |
| Dörge, H | 1 |
| Kober, IM | 1 |
| Obermayr, RP | 1 |
| Spieckermann, PG | 1 |
| Schmiedl, A | 4 |
| Schnabel, PA | 3 |
| Hachida, M | 1 |
| Lu, H | 1 |
| Ohkado, A | 1 |
| Hoshi, H | 1 |
| Gu, H | 1 |
| Nakanishi, T | 1 |
| Koyanagi, H | 1 |
| Gerber, SH | 1 |
| Heyer, C | 1 |
| Krüger, C | 1 |
| Hagl, S | 1 |
| Kübler, W | 1 |
| Haass, M | 1 |
| Stoletzki, S | 1 |
| Kausch Blecken von Schmeling, H | 1 |
| Marten, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial[NCT01681095] | Phase 2 | 110 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with all-cause mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
CK-MB measured 24 hours post-operatively (NCT01681095)
Timeframe: 24 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 20 |
| Cold Blood Cardioplegia | 24 |
CK-MB measured 48 hours post-operatively (NCT01681095)
Timeframe: 48 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 6.0 |
| Cold Blood Cardioplegia | 7.8 |
CK-MB measured pre-operatively (NCT01681095)
Timeframe: pre-operative
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 1.9 |
| Cold Blood Cardioplegia | 2.6 |
Number of participants with new or worsening of cardiac dysrhythmias (NCT01681095)
Timeframe: up to 36 hrs post surgery
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 24 |
| Cold Blood Cardioplegia | 30 |
Troponin-I measured 24 hours post-operative (NCT01681095)
Timeframe: 24 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 5.7 |
| Cold Blood Cardioplegia | 7.8 |
Troponin-I measured 48 hours post-operative (NCT01681095)
Timeframe: 48 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 3.0 |
| Cold Blood Cardioplegia | 4.8 |
Troponin-I measured pre-operatively (NCT01681095)
Timeframe: pre-operatively
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | .03 |
| Cold Blood Cardioplegia | .03 |
Number of participants with cardiovascular-related mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
Creatine phosphokinase MB isoenzyme (CK-MB) difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery
| Intervention | ng/mL (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 18.8 |
| Cold Blood Cardioplegia | 22.2 |
Troponin I values, difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery
| Intervention | ng/mL (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 9.65 |
| Cold Blood Cardioplegia | 10.15 |
LV ejection fraction by TTE, difference from baseline at 24 hours post surgery (NCT01681095)
Timeframe: Baseline and 24 hours post surgery
| Intervention | % LV volume (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | -0.06 |
| Cold Blood Cardioplegia | 1.9 |
Total time in minutes on any vasopressor or inotropic agent, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | minutes (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 340 |
| Cold Blood Cardioplegia | 582 |
Duration of stay in ICU, from ICU admission to ICU discharge (NCT01681095)
Timeframe: up to 100 days after admission
| Intervention | days (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 3 |
| Cold Blood Cardioplegia | 3 |
Number or participants fulfilling at least two of the following 3 criteria: (1) CK-MB of 100 ug/L or more and/or troponin-I of 3.0 ug/L or more, (2) appearance of new postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new hypokinetic or akinetic area in the left or right ventricle by echocardiography. (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
Number of patients receiving vasopressor or inotropic infusion for greater than 20 minutes in the operating room, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine. (NCT01681095)
Timeframe: during operative procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 47 |
| Cold Blood Cardioplegia | 43 |
time in hours from intubation to extubation, with intervening transport to the cardiac critical care unit. (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | hours (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 10.5 |
| Cold Blood Cardioplegia | 11.4 |
1 trial available for procaine and Myocardial Ischemia
| Article | Year |
|---|---|
Low-dose histidine-tryptophan-ketoglutarate solution for myocardial protection.
Topics: Adult; Aged; Cardioplegic Solutions; Coronary Artery Bypass; Coronary Disease; Creatine Kinase; Fema | 2005 |
18 other studies available for procaine and Myocardial Ischemia
| Article | Year |
|---|---|
Reduction of Cold Ischemic Injury with the Addition of Compound Glycyrrhizin in HTK Solution in a Mouse Heart Transplantation Model.
Topics: Animals; Anti-Inflammatory Agents; Cold Ischemia; Drug Evaluation, Preclinical; Glucose; Glycyrrhizi | 2020 |
Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Connexin 43; Disease Models, Animal; Gap Junc | 2019 |
Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2?
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Anesthetics, Local; Animals; Cat | 2008 |
Albumin augmentation improves condition of guinea pig hearts after 4 hr of cold ischemia.
Topics: Animals; Cardiac Output; Cell Adhesion; Coronary Vessels; Edema; Endothelium, Vascular; Glucose; Gui | 2009 |
Improved myocardial function with the addition of pinacidil to custadiol.
Topics: Animals; Blood Pressure; Coronary Circulation; Creatine Kinase; Glucose; Heart; Hypothermia, Induced | 2002 |
Total recovery of heart grafts of non-heart-beating donors after 3 hours of hypothermic coronary oxygen persufflation preservation in an orthotopic pig transplantation model.
Topics: Animals; Diacetyl; Glucose; Heart Arrest; Heart Transplantation; Heart-Lung Machine; Hypothermia, In | 2003 |
Cardioplegic solutions for myocardial preservation: analysis of hypothermic arrest, potassium arrest, and procaine arrest.
Topics: Animals; Cardioplegic Solutions; Coronary Circulation; Heart; Heart Arrest, Induced; Hypothermia, In | 1978 |
Tachycardia and myocardial ischaemia following subconjunctival injection of mydricaine (number 02) for vitrectomy procedure.
Topics: Aged; Anesthetics, Local; Atropine; Conjunctiva; Drug Therapy, Combination; Electrocardiography; Epi | 2005 |
Successful heart transplantation after 13 hours of donor heart ischemia with the use of HTK solution: a case report.
Topics: Adolescent; Glucose; Heart; Heart Transplantation; Humans; Male; Mannitol; Myocardial Ischemia; Pota | 2005 |
Changes in brain circulation in acute coronary insufficiency.
Topics: Animals; Cerebrovascular Circulation; Constriction, Pathologic; Coronary Disease; Coronary Vessels; | 1977 |
Myocardial ischemia tolerance in the newborn rat involving opioid receptors and mitochondrial K+ channels.
Topics: Animals; Decanoic Acids; Glucose; Hydroxy Acids; Mannitol; Mitochondria; Myocardial Ischemia; Myocyt | 2006 |
How beneficial is the reduction of edema formation by polyethylene glycol during cardioplegic arrest?
Topics: Animals; Blood Pressure; Cardioplegic Solutions; Coronary Circulation; Edema; Glucose; Heart; Heart | 1996 |
Cellular edema and alterations in metabolite content in the ischemic and reperfused canine heart following different forms of cardiac arrest.
Topics: Animals; Aorta; Bicarbonates; Calcium Chloride; Cardiomyopathies; Cardioplegic Solutions; Constricti | 1996 |
Effectiveness of ischemic preconditioning on long-term myocardial preservation.
Topics: Animals; Calcium; Cardioplegic Solutions; Coronary Circulation; Creatine Kinase; Glucose; Heart; In | 1998 |
Influence of Bretschneider's cardioplegia on norepinephrine release from isolated perfused guinea-pig hearts.
Topics: Adrenergic Uptake Inhibitors; Amiloride; Animals; Desipramine; Dose-Response Relationship, Drug; Fev | 1999 |
Intercalated clear cells or pale cells in the sinus node of canine hearts? An ultrastructural study.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Dogs; Female; Glucose; Heart; Heart | 2000 |
Swelling of capillary endothelial cells and cardiomyocytes in the ischaemic myocardium of artificially arrested canine hearts.
Topics: Adenosine; Allopurinol; Animals; Bicarbonates; Calcium Chloride; Capillaries; Cardioplegic Solutions | 2001 |
Different preservation of myocardial capillary endothelial cells and cardiomyocytes during and after cardioplegic ischemia (25 degrees C) of canine hearts.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Dogs; Endothelium, Vascular; Female | 2002 |